Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05030415 · ClinicalTrials.gov registry record · Early Phase 1
Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris
A Early Phase 1 study of Lichen Planus and Lichen Planus Scalp, sponsored by University of New Mexi.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05030415 is a Early Phase 1 study of Lichen Planus and Lichen Planus Scalp that has completed, run by University of New Mexi. The registered enrollment target is 9 participants, below the 140-participant average among 3 other Lichen Planus trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05030415, a Early Phase 1 study of Lichen Planus and Lichen Planus Scalp, has completed, sponsored by University of New Mexi.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia Severity Score (FFASS).
Conditions Studied
Interventions
- DRUG Ixekizumab Auto-Injector
Study Locations (1)
New Mexico
- University of New Mexico - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-08-12 |
| Est. Completion | 2024-03-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05030415
The ClinicalTrials.gov registry entry for NCT05030415 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 3 other Lichen Planus trials with a reported enrollment target (94% lower). The listed sponsor is University of New Mexi, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lichen Planus appearing as the primary indexed condition, and to 1 intervention - of which Ixekizumab Auto-Injector is the first listed.
NCT05030415 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.
Frequently Asked Questions
What is clinical trial NCT05030415 about?
NCT05030415 is a clinical study titled "Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris". To evaluate the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia Severity Score (FFASS).
What is the current status of trial NCT05030415?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2021-08-12. Estimated completion is 2024-03-25.
What conditions does trial NCT05030415 study?
This clinical trial studies the following conditions: Lichen Planus, Lichen Planus Scalp, Lichen Planopilaris.
What interventions are being tested in trial NCT05030415?
The interventions under investigation include: Ixekizumab Auto-Injector (DRUG).
Who is sponsoring clinical trial NCT05030415?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05030415 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lichen Planus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.